REVERSE: a Randomized Controlled Trial (RCT) to Ameliorate Treatment-resistant Post Traumatic Stress Disorder (PTSD) with Glucocorticoid Receptor (GR) Antagonism

Rationale:
Post-traumatic stress disorder (PTSD) is a psychiatric disorder that can develop in people who have experienced or witnessed a traumatic event. Symptoms of PTSD include flashbacks, nightmares, difficulty sleeping, difficulty concentrating, irritability, and avoidance of people, places, or activities that remind the person of the traumatic event. Even though there are effective treatments (e.g. exposure-based psychotherapies and antidepressants), not all patients respond. Glucocorticoid receptor (GR) antagonism is a potential therapy for the treatment of treatment-resistant post traumatic stress disorder (PTSD) based on the idea that PTSD may be caused or exacerbated by dysregulation of the body's stress response system, and on the results of several small clinical trials. By blocking the actions of cortisol at the GR, it is thought that GR antagonists may be able to reduce the severity of PTSD symptoms and improve treatment outcomes. Randomized controlled trials (RCT) can provide high-quality evidence on treatment efficacy, and optimize evidence-based selection of off-label treatments for patients. Therefore the aim is to investigate whether the psychological and biological sequelae of traumatic stress and PTSD can be targeted by blocking the glucocorticoid receptor (GR) using the generic drug mifepristone in a double blind, placebo controlled RCT.
Objective:
To test the hypothesis that treatment with the GR-antagonist mifepristone is more effective than placebo to reduce PTSD symptom severity in treatment-resistant PTSD.
Main trial endpoints:
Improvement of PTSD symptoms, as measured with the monthly version of the CAPS-5 (Clinician Administered PTSD scale) in patients with treatment-resistant PTSD, 4 weeks after the start of the intervention. Secondary trial endpoints
* PTSD symptom severity as measured with the weekly version of the PCL-5, from baseline till 12 weeks after the start of the intervention (T3).
* Long-term PTSD symptom severity as measured with the CAPS-5, at 12 weeks after the start of the intervention (T3).
* Loss of diagnosis (score of <26 and absence of PTSD criteria with CAPS-5), 4 weeks after the start of the intervention.
* Treatment response (minimum decrease of 10 point on the PCL-5 and CAPS-5 scores) at 1, 4 and 12 weeks after the start of the intervention.
* Other clinical outcomes 1, 4, and 12 weeks after the start the intervention:
* disability (WHO Disability Schedule 2.0; WHO-DAS II),
* sleep (Insomnia Severity Index; ISI),
* subjective stress (Perceived Stress Scale; PSS),
* anxiety symptoms (Beck Anxiety Inventory; BAI),
* depressive symptoms (IDS-SR),
* suicidal ideation and behaviour (Columbia-Suicide Severity Rating Scale).
Trial design:
The experimental protocol consists of a placebo-controlled double-blind RCT with 4 face-to-face meetings:
* baseline (T0, 2,5 hrs);
* post-intervention T1, 8 days after start (1hr);
* post-intervention T2, 4 weeks after start (2hr).
* post-intervention T3, 12 weeks (2hr).
Trial population:
60 adult patients (male/female, 18+ years), with treatment-resistant PTSD (non-response to two evidence-based PTSD treatments, at least one of which is trauma-focused psychotherapy). Intervention Patients are randomized for treatment with the GR antagonist mifepristone (1200 mg/day for 7 days) or matching placebo (daily for 7 days). Study medication will be dispensed during the baseline measurement (T0), and taken once daily for 7 consecutive days. Clinical measurements consist of clinical interviews and questionnaires. During baseline visits a pregnancy test is conducted in woman of child bearing potential (WOCBP), and blood is drawn at T1 to assess mifepristone plasma levels.
Ethical considerations relating to the clinical trial including the expected benefit to the individual subject or group of patients represented by the trial subjects as well as the nature and extent of burden and risks:
Mifepristone has been clinically used for Cushing's syndrome (anti-glucocorticoid effects) and termination of pregnancy (anti-progesterone effects) for several decades. Mifepristone is generally well-tolerated, and several double-blind studies using the identical duration and dose have shown (7 days, 1200 mg) that the safety profile of mifepristone is comparable to that of placebo treatment, and study dropouts due to side effects were higher for placebo (1.6%) than for mifepristone (1.4%). The most common adverse events (AEs) were nausea, headache, dizziness, and a dry mouth and were comparable between the mifepristone and placebo groups. With regard to mifepristone's progesterone receptor activity and its indication for pregnancy termination, WOCBP who do not agree to use a non-hormonal contraceptive method (condom) during the intervention and up to 1 month after the intervention, are strictly excluded from participating in this study.

Start Date15 Nov 2024

Sponsor / Collaborator

Stichting Onderzoek Cancer Center Amsterdam

[+1]

NCT06502158 / RecruitingPhase 1IIT

Mifepristone Versus Misoprostol for Cervical Preparation Prior to Procedural Abortion at 12 to 16 Weeks' Gestation in an Academic Medical Center: a Randomized Controlled Pilot Trial

The Investigator team hypothesizes that in a randomized trial comparing mifepristone-alone or misoprostol-alone for cervical preparation for procedural abortions at 12 to 16 weeks in hospital-based care, the proportion of patients who achieve successful cervical dilation will be different between the study groups.

Start Date31 Oct 2024

Sponsor / Collaborator

Montefiore Medical Center

NCT06394999 / Not yet recruitingPhase 3IIT

Prospective Phase III Multi-center Open-label Study of the Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive

Participants in the study will use mifepristone 50 mg once-a-week for one year as a contraceptive. With this, we want to confirm that the chances of getting pregnant while using this contraceptive are very small. We also want to demonstrate that the use of mifepristone is safe, and it does not lead to any severe health problems. We expect fewer side effects compared to other frequently used contraceptives with hormones. Mifepristone does not contain these hormones. It is important to know how people experience that use of one tablet a week.

Start Date01 Sep 2024

Sponsor / Collaborator

Academisch Ziekenhuis Leiden

[+2]

100 Clinical Results associated with Mifepristone

100 Translational Medicine associated with Mifepristone

100 Patents (Medical) associated with Mifepristone

7,523

Literatures (Medical) associated with Mifepristone

01 Sep 2025·Neural Regeneration Research

High-dose dexamethasone regulates microglial polarization via the GR/JAK1/STAT3 signaling pathway after traumatic brain injury

Article

Author: Wu, Hongbin ; Yang, Mengshi ; Deng, Yu ; Liu, Baiyun ; Bai, Miao ; Niu, Fei ; Ge, Qianqian ; Zhuang, Yuan ; Dong, Xinlong ; Xu, Xiaojian ; Zhang, Bin ; Lu, Shenghua ; Li, Hao

JOURNAL/nrgr/04.03/01300535-202509000-00023/figure1/v/2024-11-05T132919Z/r/image-tiff Although microglial polarization and neuroinflammation are crucial cellular responses after traumatic brain injury, the fundamental regulatory and functional mechanisms remain insufficiently understood. As potent anti-inflammatory agents, the use of glucocorticoids in traumatic brain injury is still controversial, and their regulatory effects on microglial polarization are not yet known. In the present study, we sought to determine whether exacerbation of traumatic brain injury caused by high-dose dexamethasone is related to its regulatory effects on microglial polarization and its mechanisms of action. In vitro cultured BV2 cells and primary microglia and a controlled cortical impact mouse model were used to investigate the effects of dexamethasone on microglial polarization. Lipopolysaccharide, dexamethasone, RU486 (a glucocorticoid receptor antagonist), and ruxolitinib (a Janus kinase 1 antagonist) were administered. RNA-sequencing data obtained from a C57BL/6 mouse model of traumatic brain injury were used to identify potential targets of dexamethasone. The Morris water maze, quantitative reverse transcription-polymerase chain reaction, western blotting, immunofluorescence and confocal microscopy analysis, and TUNEL, Nissl, and Golgi staining were performed to investigate our hypothesis. High-throughput sequencing results showed that arginase 1, a marker of M2 microglia, was significantly downregulated in the dexamethasone group compared with the traumatic brain injury group at 3 days post–traumatic brain injury. Thus dexamethasone inhibited M1 and M2 microglia, with a more pronounced inhibitory effect on M2 microglia in vitro and in vivo. Glucocorticoid receptor plays an indispensable role in microglial polarization after dexamethasone treatment following traumatic brain injury. Additionally, glucocorticoid receptor activation increased the number of apoptotic cells and neuronal death, and also decreased the density of dendritic spines. A possible downstream receptor signaling mechanism is the GR/JAK1/STAT3 pathway. Overactivation of glucocorticoid receptor by high-dose dexamethasone reduced the expression of M2 microglia, which plays an anti-inflammatory role. In contrast, inhibiting the activation of glucocorticoid receptor reduced the number of apoptotic glia and neurons and decreased the loss of dendritic spines after traumatic brain injury. Dexamethasone may exert its neurotoxic effects by inhibiting M2 microglia through the GR/JAK1/STAT3 signaling pathway.

01 Jan 2025·Journal of Ethnopharmacology

Dan’e fukang decoction reduces hemorrhage in a rat model of mifepristone induced incomplete abortion and may correlate with cell adhesion molecule signaling interference

Article

Author: Yang, Wen-jie ; Hu, Ying-Yi ; Yang, Wen-Jie ; Zhong, Rui-Hua ; Zhong, Rui-hua ; Wu, Jianhui ; Li, Guo-Ting ; Zhou, Jie-yun ; Ni, Qi-cheng ; Li, Guo-ting ; Ni, Qi-Cheng ; Yang, Ye ; Hu, Ying-yi ; Zhou, Jie-Yun ; Zhu, Yan

ETHNOPHARMACOLOGICAL RELEVANCEDan'e fukang decoction (DFD) is a traditional Chinese medicine formula. DFD obtains 10 herbs, including Salvia yunnanensis C.H.Wright (Zidanshen), Curcuma zedoaria (Christm.) Roscoe (Ezhu), Angelica sinensis (Oliv.) Diels (Danggui), Cyperus rotundus L. (Xiangfuzi), Corydalis yanhusuo (Y.H.Chou & Chun C. Hsu) W.T.Wang ex Z.Y.Su & C.Y.Wu, Bupleurum marginatum Wall. ex DC. (Yanhusuo), Sparganium stoloniferum (Buch.-Ham. ex Graebn.) Buch.-Ham. ex Juz. (Sanleng), Panax notoginseng (Burkill) F.H.Chen (Sanqi), Paeonia lactiflora Pall. (Shaoyao) and Glycyrrhiza uralensis Fisch. (Gancao). DFD is now clinically used for the treatment of menstrual irregularities, dysmenorrhea and menstrual discomfort caused by blood stasis and easing of endometriosis. Based on this, it is reasonable to presume that DFD may be effective in treating incomplete abortion and reducing postpartum bleeding, but no specific studies have been reported so far.AIM OF THE STUDYTo investigate the efficacy of Dan'e fukang decoction (DFD) in reducing prolonged vaginal bleeding followed by mifepristone induced incomplete abortion and explore the mechanisms of action of DFD in treating incomplete abortion.METHODSAn incomplete abortion model of rat was established by single intragastrically administered 8.5 mg/kg mifepristone on the 7th day of pregnancy. From the 8th day of pregnancy, the abortive rats were administered solvent, a positive control drug, or different doses of DFD, respectively for seven consecutive days. The efficacy of DFD was assessed by measuring the vaginal bleeding volume of the rats. Four coagulation parameters and platelet counts were measured. Hematoxylin and eosin (HE) staining was performed to evaluate pathological changes in the uterine embryos. Serum levels of progesterone and estrogen were measured using ELISA. Network pharmacology and transcriptomics were used to predict potential targets and pathways for DFD to reduce hemorrhage. The levels of mRNA related to cell adhesion molecules (CAMs) were detected by RT-qPCR. The levels of progesterone and estrogen receptors and the proteins associated with CAMs pathway in uterine tissues were detected by Western Blot.RESULTSDFD significantly reduced the volume of vaginal bleeding of the abortive rats and significantly downgraded the pathological scores of uterine embryos. DFD significantly increased serum levels of E2, and had no impact on serum levels of P4 and the protein expression of ER and PR in the uteri of the abortive rats. Pathways in cancer, lipid, focal adhesion and immune-related signaling were predicted to be influenced by DFD via the analysis of network pharmacology. The CAMs signaling was found the most critical pathway regulated by both mifepristone and DFD via RNA-seq assay, followed by axon guidance, basal cell carcinoma, hippo signaling pathway and neuroactive ligand-receptor interaction. Combining the two analytical methods, ICAM-1 was predicted likely the key targeted gene by DFD. Finally, DFD was validated to decrease the protein expression of ICAM-1, ITGB2, ITGB7 and RASSF5 in the uterine tissues, which correlated to suppress the CAMs signaling pathway.CONCLUSIONDFD significantly reduced hemorrhage. DFD significantly increased the serum levels of E2 and inhibited CAMs signaling pathway, which was likely to be involved in the mechanism of action of DFD facilitating residual uterine embryo expulsion in the rat model of incomplete abortion.

01 Jan 2025·Radiology Case Reports

Teratogenic effect of Misoprostol following failure of elective abortion: A case of femoral agenesis and review of the literature

Article

Author: Ben Rejeb, Oumayma ; Bannour, Imen ; Bannour, Badra ; Rouis, Nour ; Ben Abdelhafidh, Hiba ; Fathallah, Neila

Misoprostol, a synthetic analogue of prostaglandin E1, is commonly used in gynecology, particularly in combination with mifepristone for elective abortion. Although its use is widespread, the potential teratogenic effects of misoprostol in cases of failed medical abortion have not been sufficiently explored in the medical literature. Severe congenital malformations, although rare, have been reported, raising concerns about the impact of this drug on fetal development. We present a rare case of femoral agenesis observed in a woman who experienced a failed medical abortion with Misoprostol (Cytotec®), highlighting the need for a better understanding of the risks associated with fetal exposure to this drug and the implementation of rigorous follow-up measures after its use.

223

News (Medical) associated with Mifepristone

07 Nov 2024

·www.drugs.com

Using Abortion Pills Very Early in Pregnancy Is Safe, Study Finds

THURSDAY, Nov. 7, 2024 -- Abortion pills are safe and effective even very early in a pregnancy, a new study finds. Clinics and hospitals tend to defer medication abortions until a woman’s pregnancy is confirmed using ultrasound, researchers said. But abortion pills can be safely taken prior to the sixth week of pregnancy, researchers reported Nov. 6 in the New England Journal of Medicine . “Women often find out very early if they’re pregnant, and a majority also know if they want a termination and if so, want it to take place as quickly as possible,” said lead researcher author Dr. Karin Brandell , a gynecologist at Karolinska University Hospital in Sweden. Doctors prefer delaying a medication abortion until an ultrasound is performed, to rule out the risk of an ectopic pregnancy, researchers said. Ultrasound reveals a pregnancy in weeks five to six. In an ectopic pregnancy, the embryo attaches outside the uterus, usually in the fallopian tubes, researchers said. An ectopic pregnancy is not terminated by a medication abortion, and can be life-threatening for the woman. For the study, researchers analyzed data on more than 1,500 women at 26 clinics in nine countries who requested an abortion before ultrasound was able to confirm their pregnancy. These women were randomly assigned to either receive their early medication abortion as requested or have their abortion delayed until pregnancy could be confirmed by ultrasound. In both groups, more than 95% of women had a complete and successful abortion. In the delayed treatment group, 4.5% of medication abortions failed and required additional surgery. In the early group, 3% of pregnancies continued and 1.8% of women required surgery for an incomplete abortion. Overall, 1% of all participants had an ectopic pregnancy, researchers found. “Very early medical abortion was just as effective and safe to perform, even in case of an undiagnosed ectopic pregnancy,” said Dr. Kristina Gemzell-Danielsson , a professor of obstetrics and gynecology at Karolinska Institute. Women in the early group reported less pain and bleeding. In both groups, women wanted to have their abortion performed as quickly as possible. “Abortion is a political as well as a medical issue,” Brandell said. “In Sweden, a woman can repeat the procedure a week after a failed early abortion. But a woman in Texas, where abortion is banned after the sixth week, can’t,” Brandell said. “It was therefore important to show that early abortion is equivalent to current standard procedure at a later stage of pregnancy.” Researchers now want to test if a new combination of drugs for early abortion might also prove effective in treating ectopic pregnancies. They are also developing new contraceptives based on mifepristone , one of the two drugs used in a medication abortion. “It can be taken in a lower dose than for abortion to prevent unwanted pregnancies in the form of one tablet a week, or when needed,” Gemzell-Danielsson said. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

07 Nov 2024

·www.biopharmadive.com

With Trump victorious, biotech industry’s focus turns to his plans for FDA, FTC

Donald Trumps victory in the U.S. presidential election Tuesday means change is coming for federal health agencies and the industries they regulate. Its just not quite clear yet how dramatic that change might be.Trump has pledged to make America healthy again and, in embracing Robert F. Kennedy Jr., a well-known critic of vaccines and pharmaceutical companies, has signaled such a campaign could feature unorthodox or disruptive ideas.I'm going to let him go wild on health, Trump said in a campaign speech in New York last month. I'm going to let him go wild on the food. I'm going to let him go wild on medicines.The potential for Kennedy to have a role overseeing or advising on healthcare policy is focusing the drug industrys attention on how Trump might treat the Food and Drug Administration.In his first term, Trump picked more traditional choices Scott Gottlieb and then Stephen Hahn as his FDA commissioners. And while he and his administration leaned on the agency to make decisions on unproven COVID-19 treatments like hydroxychloroquine, they also put Operation Warp Speed into action, accelerating the development of safe and effective coronavirus vaccines.I think a Trump administration will pay a lot of attention to the FDA, said Holly Fernandez Lynch, an associate professor of medical ethics and health policy at the University of Pennsylvania. Obviously, the FDA was high on President Trumps radar screen last time around because of COVID.A drug policy agenda influenced by Kennedy in Trumps second term may look different. Speaking with NPR Tuesday, Kennedy said hes been instructed to rid regulatory agencies of corruption, return them to evidence-based science and end what hes termed the chronic disease epidemic. Hes also previously said on X that he hopes to promote what some physicians consider fringe areas of medical science like stem cell injections and nutraceuticals.If you work for the FDA and are part of this corrupt system, I have two messages for you: 1. Preserve your records, and 2. Pack your bags, Kennedy wrote.His focus on undoing what he deems to be regulatory suppression could have an ally in Trump. Fernandez Lynch noted Trumps recent emphasis on the right to try legislation he signed into law in 2018 is indicative of Trumps view of the agency.The fact that he keeps bringing it up suggests that he continues to think it's a big deal, said Fernandez Lynch. I do think that it gives a lot of insight into his mindset around the value of FDA or its perceived lack of value [to him].Keeping that mindset in frame suggests he would push FDA to go even deeper [in promoting] the flexibility theyre already exerting, she said.Still, analysts expect Kennedy would have difficulty winning Senate confirmation for roles leading the FDA or its parent agency, the Department of Health and Human Services. In the NPR interview, Kennedy said its not yet decided what his role might be. Other candidates might be favored for the FDA and for HHS.None of us know who's going to be appointed, said Jeffrey Jonas, the former CEO of Sage Therapeutics and currently a partner at Cure Ventures. So the question is going to be: Is [Kennedy] going to be the only voice in the room? Or is he going to be brought in to represent a particular point of view on health and drugs?The drug industry is arguably the most highly regulated industry in the world. It's really not a job for amateurs or politicians, Jonas added. We have to hope that this administration, and every administration, appoints people who are familiar with the science in an apolitical manner.While biotech leaders may view Kennedy with some trepidation, theyre more optimistic about what a Trump administration might mean for the federal governments scrutiny of mergers and acquisitions.Pharmaceutical company dealmaking plays an important role within biotech. Acquisitions generate returns for biotech investors and recycles capital as well as talent into startups working on new ideas. They can also, some argue, increase companies market power and snuff out competitors.Industry M&A has been a particular target of the Federal Trade Commission under current chair Lina Khan, a Biden administration appointee. The agency scrutinized Amgens $28 billion buy of Horizon Pharmaceuticals, tightened merger guidelines and, most worryingly for many in biotech, took the unusual step of blocking an early-stage licensing deal.With regard to FTC, theres a good chance that changing leadership there will be a positive for biotech, Daphne Zohar, the CEO of Seaport Therapeutics and previously head of PureTech Health, wrote in an email.Jonas, of Cure, holds a similar view. For many of us, our view is the FTC has been very arbitrary in its application of the rules and regulations, he said. I think a change at that office will be a benefit to the investment community, to the biotech community and, frankly, for patients and innovation.Khan's current term ends in 2028. But the president gets to designate the FTC chair, and Trump will have an opportunity to replace Commissioner Rebecca Kelly Slaughter, whose term will end in May 2025.Beyond personnel, a Trump administration could change how the federal government approaches drug pricing. In his first term, Trump floated a number of policies to cut drug costs that either failed to advance or were thwarted by legal action. Among them was a favored nations policy designed to link Medicare reimbursements to prices paid abroad. That plan is one way to control prices on a macro level, said Jonas, so that'll be one area people will be watching.“However, he appeared to back away from that idea in recent months, with his campaign telling Statin October that there is “no push“ to revive the policy.Since Trump left office, the Biden administration has also enacted the Inflation Reduction Act, which for the first time granted Medicare the authority to negotiate drug prices. Its unclear how the incoming administration might adjust implementation of the law.“The range of possible outcomes for the industry on drug pricing policy in a second Trump term is quite substantial, and the outlook for the new Medicare drug price negotiation program is perhaps the best case in point,“ wrote Rick Weissenstein, an analyst at Cowen, in a client note.A second Trump term could also rekindle scrutiny of U.S. firms ties to Chinese companies. His administration may additionally seek to limit the availability of the abortion pill mifepristone, which the FDA under the Biden administration has sought to defend.I expect a Musk-ian deregulation of the industry, which could offer some positive elements in our efforts to bring medicines to patients as long as we maintain strong scientific standards, said John Maraganore, the former CEO of Alnylam Pharmaceuticals and now a board member of several biotechs. '

Executive ChangeVaccine

23 Oct 2024

·www.biospace.com

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on October 30, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here . Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here . A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therapeutics For over 25 years, Corcept’s focus on cortisol modulation and its potential to treat patients with a wide variety of serious disorders has led to the discovery of more than 1,000 proprietary selective cortisol modulators. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS) and liver disease. In February 2012, the company introduced Korlym ® , the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Corcept is headquartered in Redwood City, California. For more information, visit Corcept.com. Contacts Investor inquiries: ir@corcept.com Media inquiries: communications@corcept.com

Drug ApprovalFinancial Statement

100 Deals associated with Mifepristone

External Link

KEGG	Wiki	ATC	Drug Bank
D00585	Mifepristone	G03XB01	DB00834

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Induced Abortion	JP	Linepharma	28 Apr 2023
Cushing Syndrome	US	Corcept Therapeutics, Inc.	17 Feb 2012
Induced termination of pregnancy in second trimester	US	Danco Laboratories LLC	28 Sep 2000
Contraception	CN	Hongjian Pharmaceutical (Shanghai) Co., Ltd.	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Endogenous Cushing Syndrome	Preclinical	US	Corcept Therapeutics, Inc.	01 Dec 2007
Weight Gain	Preclinical	IN	Corcept Therapeutics, Inc.	01 Mar 2007
Depressive Disorder, Major	Preclinical	US	Corcept Therapeutics, Inc.	01 Sep 2004
Pelizaeus-Merzbacher Disease	Preclinical	US	Corcept Therapeutics, Inc.	01 Sep 2004
Psychotic Disorders	Preclinical	US	Corcept Therapeutics, Inc.	01 Sep 2004
Pituitary ACTH Hypersecretion	Discovery	US	Corcept Therapeutics, Inc.	01 Nov 2010
Affective Disorders, Psychotic	Discovery	US	Corcept Therapeutics, Inc.	01 Mar 2008
Depressive Disorder, Major	Discovery	US	Corcept Therapeutics, Inc.	01 Sep 2004
Psychotic Disorders	Discovery	US	Corcept Therapeutics, Inc.	01 Sep 2004
Alzheimer Disease	Discovery	US	Corcept Therapeutics, Inc.	01 Apr 2003

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03913104 (CTgov)	Phase 4	Abortion, Spontaneous	536	Mifepristone	jdrqoijfku(ryzdyseahw) = akhzpovrez mcgqmixbpi (xwdloqpgsx, ohgeleardy - amogksvklf) View more	-	14 Aug 2024
NCT05097326 (MiLI, CTgov)	Phase 3	-	30	Mifepristone (Mifepristone)	ggbqampoeo(stxltnecdh) = yllkiyoejh wyygujwmxp (jsepeorqcv, nqeywtyhcg - nwkeiksfhn) View more	-	31 Jul 2024
				Misoprostol (Misoprostol)	ggbqampoeo(stxltnecdh) = zdzgvcjffq wyygujwmxp (jsepeorqcv, kvnkrtrect - ezdolfgmaz) View more
NCT02788981 (CTgov)	Phase 2	-	29	nab-paclitaxel+Mifepristone (Nab-Paclitaxel+Mifepristone)	jkzkqpqrij(qpnuxwhldj) = ebmollketx yvruokziqp (nuyuaglmzo, bzqamyzxig - cabhipoblj) View more	-	16 Feb 2024
				Placebo+nab-paclitaxel (Nab-Paclitaxel+Placebo)	jkzkqpqrij(qpnuxwhldj) = wewosizjmg yvruokziqp (nuyuaglmzo, pkmnhckwvq - gwntadhibr) View more
NCT03520439 (Pubmed)	Phase 2/3	Adenomyosis	134	Mifepristone 10 mg	nbkimnpmez(wmevchjmok) = uapqvtwook fawmkpqjrh (quzisrjpjd ) View more	Positive	01 Jun 2023
				Placebo	nbkimnpmez(wmevchjmok) = uoscjobvua fawmkpqjrh (quzisrjpjd ) View more
NCT02243709 (CTgov)	Phase 1/2	Alcohol Use Disorder	32	Mifepristone 600-mg/day or placebo for a week	qxfojwwqyf(kcgboevrrb) = ytoreulpia ehulxsmkin (xsnerwqcbc, nrdkdzvhyb - wjhvfsbzji) View more	-	01 Jun 2023
NCT03225547 (ASCO2023) Manual	Phase 2	HER2-negative breast cancer HER2 Negative	18	mifepristone 300 mg+pembrolizumab 200 mg	(mytelplqhe) = dngckhnrtc rtbfkbobzh (clwcycxojr ) View more	Positive	26 May 2023
NCT02788981 (ASCO2023) Manual	Phase 2	Advanced Triple-Negative Breast Carcinoma	29	nab-paclitaxel+Mifepristone	(btzqcfaibg) = xaquldlnlz lkzudlbaqa (qijvxkkgav ) View more	Negative	26 May 2023
				nab-paclitaxel+Placebo	(btzqcfaibg) = lxeindqyzj lkzudlbaqa (qijvxkkgav ) View more
AACR2023	Not Applicable	Small Cell Lung Cancer	-	Mifepristone	iilltuidhj(rwzamwfllh) = tqpfsjhrkr opsphlrtga (pbfslazkvp )	-	04 Apr 2023
NCT03052400 (CTgov)	Phase 2	Diabetes Mellitus, Type 2 \| Insulin Resistance	8	Mifepristone 600 mg daily (Mifepristone 600 mg Daily)	ihiadwccfc(jqkzochxkc) = idabdsixef xbsivcowik (fdcfpkebxp, ulynmwnqpw - bpxooffvhm) View more	-	19 Oct 2022
				Placebo (Placebo)	ihiadwccfc(jqkzochxkc) = euahkakytu xbsivcowik (fdcfpkebxp, lmhxwukxif - kcyjxfyxof) View more
NCT02012296 (CTgov)	Phase 1/2	Recurrent Prostate Carcinoma \| Metastatic castration-resistant prostate cancer	88	pharmacological study+enzalutamide (Treatment (Enzalutamide))	xqunccgrwv(qgmozrldoe) = qgyovnnzil rmnjsqwast (geqxkrhcsv, dsrekcebwy - nfseytwikg) View more	-	13 Jul 2022
				pharmacological study+enzalutamide+mifepristone (Treatment (Enzalutamide, Mifepristone))	xqunccgrwv(qgmozrldoe) = lrxdlefczg rmnjsqwast (geqxkrhcsv, cwvmqjigon - hojbocgmbz) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis